Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center

Research output: Chapter in Book/Report/Conference proceedingConference contribution

38 Citations (Scopus)

Abstract

As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from ageand sex-matched population obtained from the Health for All database, and also to literature data.Atotal of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity.Patientswere 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4-12.5) and cervix cancer (SIR 1.7, 95%CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages76-82
Number of pages7
Volume1108
DOIs
Publication statusPublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Systemic Lupus Erythematosus
Tumors
Skin
Adrenal Cortex Hormones
Screening
Health
Neoplasms
Morbidity
Uterine Cervical Neoplasms
Mortality
Incidence
Skin Neoplasms
Hematologic Neoplasms
Life Expectancy
Urinary Bladder Neoplasms
Ovarian Neoplasms
Non-Hodgkin's Lymphoma
Therapeutics
Databases
Breast Neoplasms

Keywords

  • Cancer
  • Lupus
  • Lymphoma
  • Malignancy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tarr, T., Györffy, B., Szekanecz, É., Bhattoa, H., Zeher, M., Szegedi, G., & Kiss, E. (2007). Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center. In Annals of the New York Academy of Sciences (Vol. 1108, pp. 76-82). (Annals of the New York Academy of Sciences; Vol. 1108). https://doi.org/10.1196/annals.1422.008

Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus : Results from a single center. / Tarr, T.; Györffy, B.; Szekanecz, Éva; Bhattoa, H.; Zeher, M.; Szegedi, G.; Kiss, E.

Annals of the New York Academy of Sciences. Vol. 1108 2007. p. 76-82 (Annals of the New York Academy of Sciences; Vol. 1108).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Tarr, T, Györffy, B, Szekanecz, É, Bhattoa, H, Zeher, M, Szegedi, G & Kiss, E 2007, Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center. in Annals of the New York Academy of Sciences. vol. 1108, Annals of the New York Academy of Sciences, vol. 1108, pp. 76-82. https://doi.org/10.1196/annals.1422.008
Tarr T, Györffy B, Szekanecz É, Bhattoa H, Zeher M, Szegedi G et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center. In Annals of the New York Academy of Sciences. Vol. 1108. 2007. p. 76-82. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1422.008
Tarr, T. ; Györffy, B. ; Szekanecz, Éva ; Bhattoa, H. ; Zeher, M. ; Szegedi, G. ; Kiss, E. / Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus : Results from a single center. Annals of the New York Academy of Sciences. Vol. 1108 2007. pp. 76-82 (Annals of the New York Academy of Sciences).
@inproceedings{d1ec6e548fcc4254b963459c4fc14ffc,
title = "Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: Results from a single center",
abstract = "As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from ageand sex-matched population obtained from the Health for All database, and also to literature data.Atotal of 37 patients presented with cancer, reflecting 4.3{\%} cancer-associated morbidity.Patientswere 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95{\%}CI 0.4-12.5) and cervix cancer (SIR 1.7, 95{\%}CI 0.6-4.1). Although 76{\%} of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11{\%} (18/164). This peaked during the last 4 years of the study period (8/24, 33{\%}). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.",
keywords = "Cancer, Lupus, Lymphoma, Malignancy",
author = "T. Tarr and B. Gy{\"o}rffy and {\'E}va Szekanecz and H. Bhattoa and M. Zeher and G. Szegedi and E. Kiss",
year = "2007",
month = "6",
doi = "10.1196/annals.1422.008",
language = "English",
isbn = "157331708X",
volume = "1108",
series = "Annals of the New York Academy of Sciences",
pages = "76--82",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus

T2 - Results from a single center

AU - Tarr, T.

AU - Györffy, B.

AU - Szekanecz, Éva

AU - Bhattoa, H.

AU - Zeher, M.

AU - Szegedi, G.

AU - Kiss, E.

PY - 2007/6

Y1 - 2007/6

N2 - As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from ageand sex-matched population obtained from the Health for All database, and also to literature data.Atotal of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity.Patientswere 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4-12.5) and cervix cancer (SIR 1.7, 95%CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.

AB - As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from ageand sex-matched population obtained from the Health for All database, and also to literature data.Atotal of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity.Patientswere 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95%CI 0.4-12.5) and cervix cancer (SIR 1.7, 95%CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.

KW - Cancer

KW - Lupus

KW - Lymphoma

KW - Malignancy

UR - http://www.scopus.com/inward/record.url?scp=34948884016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948884016&partnerID=8YFLogxK

U2 - 10.1196/annals.1422.008

DO - 10.1196/annals.1422.008

M3 - Conference contribution

C2 - 17893972

AN - SCOPUS:34948884016

SN - 157331708X

SN - 9781573317085

VL - 1108

T3 - Annals of the New York Academy of Sciences

SP - 76

EP - 82

BT - Annals of the New York Academy of Sciences

ER -